PMID

Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of First-In-Class Drug Candidate XCE853 – A Potent Inhibitor of Cancer Metabolism

Retrieved on: 
월요일, 5월 6, 2024
Data Management, Biotechnology, Technology, Health, Pharmaceutical, Oncology, Health Technology, Other Technology, Software, Artificial Intelligence, Clinical Trials, Enzyme, Cancer, Prostate, IP, D.C, PDI, Proteinopathy, PMID, Drug resistance, Machine learning, The Journal of Pathology, Breast, MD, Cell, Artificial intelligence, Leukemia, ISSN, Cancer Medicine, Molecular biology, CNS, Giaquinto, Algorithm, Patient, Neoplasm, Lung, Death, Head, Biomarker, Drug development, Therapy, Clinician, Journal, Ovarian cancer, Brain, Oncology Reports, Pharmaceutical industry

(NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications.

Key Points: 
  • (NASDAQ: LTRN), a leading artificial intelligence (AI) oncology drug discovery and development company, today announced a strategic AI-driven collaboration with French biotechnology company, Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase (PDI) (1) inhibitor drug candidate XCE853 in novel and targeted cancer indications.
  • Oregon Therapeutics is developing XCE853 in various cancer indications, including drug-resistant ovarian and pancreatic cancer, certain hematological cancers and several pediatric cancers including CNS cancers.
  • Oregon Therapeutic’s lead drug-candidate XCE853 is known to target PDIs of specific interest for cancer.
  • Oregon Therapeutics is entitled to financial benefits resulting from the out licensing of the background IP to Lantern Pharma.

Peanuts and Peanut Butter Support Women's Health

Retrieved on: 
수요일, 5월 8, 2024
Snack, Mortality, Adolescence, Nutrition, Risk, Mineral, Nutrition and Cancer, PMID, Grain boundary strengthening, Sport, Niacin, Death, American Academy of Pediatrics, PubMed, Parent, Water, INT, Choline, Food, Mother, Neurosurgery, Control, Cancer, Phytosterol, Journal, Peanut, American Heart Association, Deficit spending, Alzheimer's disease, Cyrus the Great, American Academy, Brain, Iron, Randomized controlled trial, Cardiovascular disease, Dementia, Arginine, Zinc, Vitamin, Infant, Infection, Choking, Meta-analysis, Consumer, Health, Research, Taste, Dicarboxylic acid, Food industry, Exercise, Sterling, Lung, Pediatrics, Multimedia, Fruit, Breast milk, Pinterest, Meal, Stomach, Habit, Disease, PubMed Central, Nut, General Population (album), Growth, Dietary supplement

To help women protect their health, The Peanut Institute is sharing information on the benefits that regular consumption of peanuts and peanut butter deliver to females at every stage of life.

Key Points: 
  • To help women protect their health, The Peanut Institute is sharing information on the benefits that regular consumption of peanuts and peanut butter deliver to females at every stage of life.
  • Initially, parents can thin a very small amount of peanut butter or peanut powder with water and mix it into rice cereal.
  • "For example, offering healthy snacks like fresh veggies or fruit paired with peanut butter or peanuts is a great option.
  • For more health news and tasty recipes that include peanuts and peanut butter, visit PeanutInstitute.com or follow Facebook , Twitter , Instagram , LinkedIn and Pinterest .

Implantica's RefluxStop™ is now available in seven hospitals in Spain adding two new centers of excellence

Retrieved on: 
목요일, 5월 2, 2024
Certification, PMID, Cancer, Esophagitis, Surgeon, Dysphagia, Patient, Prevalence, Barrett's esophagus, GERD

), a medtech company at the forefront of bringing advanced technology into the body, announces that Dra.

Key Points: 
  • ), a medtech company at the forefront of bringing advanced technology into the body, announces that Dra.
  • More patients in Spain will have access to the innovative RefluxStop™ procedure now, given that a total of seven anti-reflux centers of excellence in the country regularly perform the procedure.
  • "It's a new day we've long awaited in the world of surgical GERD treatment," says Dra.
  • She continues, "I'm pleased to see that RefluxStop does not encircle the food passageway and restores the body's natural physiology.

The geko™ device is now available through the NHS Supply Chain

Retrieved on: 
수요일, 5월 1, 2024
Leg, Supply, Pain, Patient, Knee, Cancer, BMJ Open, NHS, Acceleration, Calf, DOI, Hope, National Health Service, Hospital, Skin, PMID, SOC, Recurrence, Common fibular nerve, Carbon, INT, IWJ, Quality-adjusted life year, Mouth ulcer, Nursing, Health, Cardiovascular disease, Standard of care, Wound healing, RCT, Life imprisonment, Quality of life, Anxiety

HIGH WYCOMBE, England, May 1, 2024 /PRNewswire/ -- UK-based medical device manufacturer Firstkind Ltd, a subsidiary of Sky Medical Technology Ltd, today announced the geko device is available through the UK NHS Supply Chain. The Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organisations across England and Wales.

Key Points: 
  • HIGH WYCOMBE, England, May 1, 2024 /PRNewswire/ -- UK-based medical device manufacturer Firstkind Ltd, a subsidiary of Sky Medical Technology Ltd, today announced the geko device is available through the UK NHS Supply Chain .
  • The Supply Chain manages the sourcing, delivery and supply of healthcare products and services for NHS trusts and healthcare organisations across England and Wales.
  • "We're delighted to be listed on the NHS Supply Chain," said Bernard Ross, CEO and Founder of Sky Medical Technology.
  • Now with this wider access, through the NHS Supply Chain, geko device ease of ordering will further help NHS wound care nurses reduce the time managing wounds."

Implantica Announces Real-World Clinical Data from over 200 Patients treated across five RefluxStop™ Centers in Europe Presented at SAGES in Cleveland

Retrieved on: 
화요일, 4월 30, 2024
FDA, Society, Certification, Gastroesophageal reflux disease, Hospital, PMID, Surgeon, Research, Dexlansoprazole, Data, Patient, GERD, Quality of life, Growth, CE, Medical device

This highly esteemed conference is the biggest meeting in the world dedicated specifically to gastrointestinal and endoscopic surgery.

Key Points: 
  • This highly esteemed conference is the biggest meeting in the world dedicated specifically to gastrointestinal and endoscopic surgery.
  • Some 2,500 SAGES members, representing the world-leading experts in gastrointestinal and endoscopic surgery, attended the SAGES Annual Meeting in Cleveland, Ohio on April 17-20.
  • It's a credit to the ongoing enthusiasm for RefluxStop™ to see the latest clinical data from five world-renowned European centers of excellence in the treatment of acid reflux diseases, presented at SAGES.
  • Dr. Forsell goes on to say, "There has been an immense interest and support in RefluxStop™ therapy from the US surgeons and scientific experts.

Lantern Pharma Receives Regulatory Approval to Expand Harmonic™ Clinical Trial for Non-Small Cell Lung Cancer in Never-Smokers into Japan and Taiwan

Retrieved on: 
월요일, 4월 22, 2024
Technology, Clinical Trials, Health Technology, Software, Biotechnology, Pharmaceutical, Health, Data Management, Oncology, Artificial Intelligence, Education, National Cancer Center, MET, D.C, Lung cancer, Woman, PMID, Progression-free survival, Harmonic, Machine learning, AME Publishing Company, ClinicalTrials.gov, Collection, Artificial intelligence, IPhone, Adenocarcinoma, ROS1, Disease, Incidence, Patient, Pemetrexed, TMB, SOC, Neoplasm, Lung, ALK, EGFR, NSCLC, Carboplatin, Overalls, Gene, TK, Pharmaceutical industry

Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers (LCINS) has been increasing gradually over time, according to a publication in Translational Lung Cancer Research (1).

Key Points: 
  • Approximately one third of all lung cancer patients in East Asia are never-smokers and the proportion of lung cancer in never smokers (LCINS) has been increasing gradually over time, according to a publication in Translational Lung Cancer Research (1).
  • LCINS are histologically, mutationally, and epidemiologically distinct from smoking-related lung cancers and occur almost exclusively as adenocarcinomas and most commonly in women and individuals of Asian ancestry.
  • Dr. Goto will now lead the trial in Japan, where the incidence of non-small cell lung cancer (NSCLC) in never-smokers is double or more than that of the United States.
  • In addition, LP-300 has been administered in multiple clinical trials to more than 1,000 people and has been generally well tolerated.

BioRestorative Therapies Partners with Galen Patient Recruitment to Accelerate Completion of Enrollment in Phase 2 Trial of BRTX-100 in Chronic Lumbar Disc Disease

Retrieved on: 
월요일, 4월 8, 2024
Online, Systematic review, PMID, Partnership, Clinical trial, Meta-analysis, Safety, Pharmaceutical industry

MELVILLE, N.Y., April 08, 2024 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a clinical stage company focused on stem cell-based therapies, today announced a collaboration with Galen Patient Recruitment, Inc. (“Galen”) which, combined with the recent expansion of clinical trial capacity from approximately 10 to 30 participants per month, is expected to help accelerate the completion of patient enrollment in the ongoing Phase 2 study of BioRestorative’s lead clinical candidate, BRTX-100, in chronic lumbar disc disease (“cLDD”).

Key Points: 
  • BRTX-100 is a novel cell-based therapeutic engineered to target areas of the body that have little blood flow.
  • The safety and efficacy of BRTX-100 in treating cLDD is being evaluated in a Phase 2, prospective, randomized, double-blinded and controlled study.
  • A total of up to 99 eligible subjects will be enrolled at up to 16 clinical sites in the United States.
  • Subjects included in the trial will be randomized 2:1 to receive either BRTX-100 or placebo.

OneOme Introduces RightMed Oncology: Empowering Clinicians to Personalize Treatment and Reduce Toxicity Risk with Pharmacogenomics

Retrieved on: 
화요일, 4월 2, 2024
FDA, Other Health, Practice Management, Pharmaceutical, Surgery, Managed Care, Oncology, Mental Health, Hospitals, Genetics, Clinical Trials, Biotechnology, Science, Other Science, Research, Health, Toxicity, DPYD, Irinotecan, Clinical professor, PMID, UGT1A1, Risk, Mayo Clinic, Mental health, Wastewater treatment, Cancer, Doctor of Philosophy, MD, Medicine, E pluribus unum, Safety, Patient safety, Pain management, DPD, Colorectal cancer, Vomiting, Clinical Pharmacogenetics Implementation Consortium, Pharmaceutical industry

The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.

Key Points: 
  • The RightMed oncology portfolio empowers innovative health systems, oncology practices and prescribers to be as focused or comprehensive as their program requires.
  • Using PGx can inform usage and dosage decisions for a wide range of chemotherapy and supportive care medications.
  • For more information about RightMed Oncology, please visit OneOmeInstitute.com/Oncology or reach out directly to discuss a PGx program for your health system.
  • OneOme aims to improve patient safety, reduce overall cost of care, and improve patients' health outcomes.

Spirair, Developer of the First and Only Minimally Invasive Therapy for Mechanical Correction of Nasal Septal Deviation, Announces Appointment of Benjamin Bishop as Chief Executive Officer

Retrieved on: 
화요일, 3월 12, 2024
Surgery, Medical Devices, Health, Health Technology, Medical Supplies, NSD, Clinical Otolaryngology, PMID, Patient, Acquisition, NSR, Stanford University, NAO, Otorhinolaryngology, ENT, Therapy, Septum, Marketing, IRB, Pharmaceutical industry

Spirair™, an early-stage company pioneering minimally invasive solutions that help ENTs advance care for their patients, today announced the appointment of Benjamin Bishop as its chief executive officer.

Key Points: 
  • Spirair™, an early-stage company pioneering minimally invasive solutions that help ENTs advance care for their patients, today announced the appointment of Benjamin Bishop as its chief executive officer.
  • The company is developing a novel therapy for symptomatic nasal septal deviation (NSD) that supports and straightens minor deviations in the septum with a bioabsorbable implant.
  • Treatment options for symptomatic NSD have been limited to either over-the-counter medications to alleviate symptoms or invasive surgical techniques to address the structural issues that cause these symptoms.
  • were co-fellows in the program and identified an opportunity in the ENT space when they discovered the unmet need for a minimally invasive nasal septal deviation correction therapy to help address nasal airway obstruction.

Implantica submits U.S. FDA Premarket Approval (PMA) application for RefluxStop® (first module)

Retrieved on: 
수요일, 3월 27, 2024
Cancer, PPI, CE, PMID, Patient, Internet, PMA, Literature, File, Gastroesophageal reflux disease, FDA, Certification, Pharmaceutical industry

The U.S. FDA has agreed to a modular submission process for the RefluxStop PMA application.

Key Points: 
  • The U.S. FDA has agreed to a modular submission process for the RefluxStop PMA application.
  • This process provides for ongoing review and feedback from the FDA as the modules are submitted.
  • The second and third (final) modules are anticipated to be submitted to the FDA in three-month intervals later this year.
  • Dr. Peter Forsell, CEO of Implantica, says, "This FDA filing is a key fundamental milestone for RefluxStop®3 and puts us in motion for the U.S. launch preparation ahead of the pending FDA approval.